1. Bark, K. H., Lee, W. P., Diehl, L. J., Ross, J., Gribling, P., Zhang, Y., Nguyen, K., van Bruggen, N., Hurst, S. and Carano, R. A. (2004). Quantification of bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis, Arthritis Rheum. 50, 3377–3386.
2. Barthold, P. M., Shelley, H. and Vernon-Roberts B. (1989). Effect of cyclosporin A on connective tissue deposition in experimental inflammatory lesions, Matrix 9, 293–300.
3. Billingham, M. E. J. (1990). Models of arthritis and the search for anti-arthritic drugs, in: Antirheumatic Drugs, Orme, M. C. E. (Ed.), pp. 1–47. Pergamon Press, New York, NY.
4. Bloxham, D. P., Bradshaw, D., Cashin, C. H., Dodge, B. B., Lewis, E. J., Westmacott, D. and Self, C. R. (1990). Biologic properties of Romazerit (Ro 31-3948), a potential disease modifying anti-rheumatic drug, J. Pharmacol. Exp. Ther. 252, 1331–1340.
5. Borel, J. F., Feurer, C., Magneé, C. and Stähelin H. (1972). Effects of the new anti-lymphocytic peptide cyclosporin A in animals, Immunology 32, 1017–1025.